iiinova — where your digital self keeps evolving

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 13/10/2026

🎉 Exciting news! The first participant has been recruited to the RADIO-TB trial. RADIO-TB is testing a shorter treatment for early-stage TB found via community chest X-ray screening. 🔗 Read more: www.innovative-ctu.ucl.ac.uk/news/news-st... #Tuberculosis #TB #ClinicalResearch #GlobalHealth

innovative-ctu.ucl.ac.uk

First participant recruited into the landmark RADIO-TB trial | UCL Innovative Clinical Trials Unit

021

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 12/10/2026

Missed #AIDS2026? Catch up with one of the conference's highlighted sessions. Watch Mutsa Bwakura-Dangarembizi present results from our LATA trial in the Co-Chairs' Choice session. ▶️ Start at 28:36: plus.iasociety.org/webcasts/aid... @iasociety.bsky.social #HIVResearch #PaediatricHIV

plus.iasociety.org

AIDS 2026: Co-Chairs' Choice | IAS Plus

000

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 07/10/2026

📢 We're excited to announce the launch of our free online course, co-developed with PPI contributors, to help people understand clinical trials and get involved in health research. 🔗 www.innovative-ctu.ucl.ac.uk/patients-pub... #PPI #ClinicalTrials #HealthResearch

innovative-ctu.ucl.ac.uk

PPI contributors course | UCL Innovative Clinical Trials Unit

031

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 24/09/2026

📢 Have experience with clinical trials and PPI? Join the STAMPEDE3 PPI Group to help shape a prostate cancer trial exploring personalised treatment approaches. We're looking for men with lived experience of prostate cancer. ✍️ Apply by 30 Sept by emailing mrcctu.ppiadvice@ucl.ac.uk.

001

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 23/09/2026

Working in clinical trials and want to understand the meanings of common statistical terms used in clinical trials? Join our 4-day course to learn what’s important and why, and gain an understanding of statistical methods and analyses. 📅 2-5 Nov 2026 🔗 bit.ly/4c7zKyN

Poster, it reads "An introduction to design and analysis of clinical trials: statistics for non-statisticians
2-5 November 2026
9:30-12:45 (UK time)
Online via Zoom
More info/registration - QR code

021

Reposted by UCL Innovative Clinical Trials Unit

MS Society UK @mssocietyuk.bsky.social · 17/09/2026

We’re excited to announce the interim results of our Octopus trial. Octopus is a multi-stage, multi-arm clinical trial, transforming the way we test treatments for progressive MS. 🔬 Professor Jeremy Chataway, chief investigator, shares the interim results. Read more: mssoc.uk/3TyjTmA

011

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 22/09/2026

This #UrologicalCancerAwarenessMonth, learn about #STAMPEDE2, a trial investigating whether SABR (targeted radiotherapy) and 177Lu-PSMA-617 (nuclear medicine) can improve outcomes for people with advanced prostate cancer when added to standard care. 🔗More about STAMPEDE2: buff.ly/kiFkZ1w

innovative-ctu.ucl.ac.uk

STAMPEDE2 | UCL Innovative Clinical Trials Unit

000

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 18/09/2026

Young people living with HIV manage their condition better when their antiretroviral therapy is given by injections every eight weeks, rather than in the form of daily tablets, according to results from the LATA trial www.innovative-ctu.ucl.ac.uk/news/news-st...

innovative-ctu.ucl.ac.uk

HIV injections work better than tablets for young people | UCL Innovative Clinical Trials Unit

012

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 17/09/2026

🚨 Exciting interim results from the OCTOPUS trial! Alpha-lipoic acid shows early promise in slowing progression of MS and will move to the next stage of the trial. A milestone for innovative #MAMS trials in MS. 🔗 Read more: www.innovative-ctu.ucl.ac.uk/news/news-st... @mssocietyuk.bsky.social

innovative-ctu.ucl.ac.uk

Alpha-lipoic acid shows ‘early promise’ to treat progressive multiple sclerosis | UCL Innovative Clinical Trials Unit

112

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 15/09/2026

If you're at #ICTMC2026 this week, make sure to check out the Data-enabled trials session featuring researchers from the Transforming Data for Trials team. 🗓️ Wed 16 Sep, 3:45- 5 PM 📍 Hall 9 🔗 inconference.eventsair.com/ictmc-2026 #ClinicalTrials #ICTMC2026 #HDRUK #TDfT

inconference.eventsair.com

ICTMC 2026, ICC BIrmingham - ICTMC 2026 - ICC Birmingham

010

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 14/09/2026

📢 Attending #ICTMC2026? Don't miss the keynote from Matt Sydes (mattsydes.bsky.social), Honorary Prof. of Clinical Trials & Methodology. 🗣️ "Bringing new treatments to patients: improving clinical trials with healthcare systems data" 🗓️ 16 Sept, 11:30–12:30, Hall 1 🔗 buff.ly/hYjovbd #TDfT #HDRUK

inconference.eventsair.com

ICTMC 2026, ICC BIrmingham - ICTMC 2026 - ICC Birmingham

010

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 10/09/2026

📢 Heading to Birmingham for #ICTMC2026? Our #ClinicalTrials methodology researchers will be presenting talks, posters and workshops throughout the conference. 🔗 View the full schedule and find out where to meet the team: www.innovative-ctu.ucl.ac.uk/news/news-st...

$Innovative Clinical Trials Unit at ICTMC 2026 Oral presentations Tuesday 15 September Missing data and infographics. 10:45-12PM (BST). Missing viral load measurments in HIV treatment trials: a comparison of approaches (Tra My Pham) Wednesday 16 September Conduct- Data-enabled trials. 3:45-5PM (BST). Streamlining event ascertainment from health systems data: accuracy of the SCORE-CVD myocardial infraction phenotyping algorithm in a prostate cancer trial (Sharon Love, Macey Murray) 3:45-5PM (BST). Health systems data for evaluating mortality outcomes in randomised prostate cancer trials: A data utility comparison study within the STAMPEDE and PATCH trials (Grisma Patel) Conduct-Trial management, trial monitoring and quality control. 3:45-5PM (BST). Smarter Processes for Enhanced Clinical TRial Efficiency (SPECTRE): Identifying Inefficiencies in site set-up (Aaron horsey) Analysis - Borrowing of information. 1:45-2:45PM (BST). A comparison of different information-borrowing approaches in a trial evaluating dolutegravir-based antiretroviral therapy in HIV-infected children (Wenyue Li)$

Innovative Clinical Trials Unit at ICTMC 2026
Oral presentations
Thursday 17 September
Design-Adaptive and innovative designs. 10:40-11:40AM (BST): Recommendation-wise type 1 error: a new measure for clinical trials using Bayesian borrowing for precision medicine (Ian White)
Analysis-Data-enabled trials and secondary data. 10:40-11:40AM (BST). The need for fully effective federated analytics of data sources of clinical trials (Stella Fabiane)

Innovative Clinical Trials Unit at ICTMC 2026
Posters
COSSMaT Study- Core Outcome Set for Severe Malaria Treatment Trials - Gideon Asamoah
From Paperwork to Partnership: A Collaborative and Risk-Proportionate Approach to Trial Database Development - Lindsey Masters
Emulating a randomised controlled trial based on the ODYSSEY trial design using paediatric HIV cohort data - Jerome Johnson
Measurement and reporting of menstrual blood loss outcomes in clinical trials which assess heavy menstrual bleeding: a comprehensive review - Lily Nicholson
Understanding the current state of knowledge around using Health Systems Data in clinical trials - Macey Murray
Assessing the utility of routinely collected Health Systems Data and Case Report Form data in Randomised Controlled Trials: A Systematic Review of DUCkS - Grisma Patel
Evidence‑Informed Consent Guidance for Trustworthy Access to Health Systems Data for Trials (CrossWord): Insights from a multistakeholder collaborative approach - Kate Roberts

021

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 07/09/2026

As we mark #WorldRadiotherapyAwarenessDay, new findings from the ARCHERY study highlight the potential of AI to expand access to high-quality radiotherapy planning in low- and middle-income countries. 🔗Read more about the results: www.innovative-ctu.ucl.ac.uk/news/news-st...

innovative-ctu.ucl.ac.uk

AI tool for radiotherapy can support the global effort to eliminate cervical cancer | UCL Innovative Clinical Trials Unit

000

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 01/09/2026

September is #GynaecologicalCancerAwarenessMonth, and we're highlighting the ICON8B trial. The study found that women with advanced #OvarianCancer lived longer when chemotherapy was given weekly alongside bevacizumab, compared with the standard treatment every 3 weeks. 🔗Read more: buff.ly/QyYtc9S

innovative-ctu.ucl.ac.uk

Weekly chemotherapy with bevacizumab improves ovarian cancer survival compared to having it once every three weeks | UCL Innovative Clinical Trials Unit

20 Oct 2025

000

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 24/08/2026

📢 We're hiring! We are looking for a Science Communications Officer (maternity cover). A varied role creating content that showcases the impact of national & international trials in cancer, Parkinson's disease, paediatric HIV, multiple sclerosis & more. 📅 Apply by 10 Sept 2026 🔗 buff.ly/sdYteSn

ucl.ac.uk

UCL – University College London

UCL is consistently ranked as one of the top ten universities in the world (QS World University Rankings 2010-2022) and is No.2 in the UK for research power (Research Excellence Framework 2021).

011

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 11/08/2026

Working in clinical trials and want to make better use of routinely collected healthcare data? Learn how to compare datasets and assess their suitability for specific research questions at our upcoming DUCks workshop. 📅 22 Oct 2026, 10-1 (UK time) 🔗 More information: bit.ly/3RHiUQf

Flyer DUCkS workshop
Thur 22 October 2026
10-1 (UK time)
In person - 90 High Holborn, London
More info/registration: QR code

002

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 29/07/2026

🚨 Exciting results from the LATA trial at #AIDS2026! LATA showed that having injections every 8 weeks was better at keeping HIV under control than taking daily tablets for young people living with HIV. 🔗 Read more: www.innovative-ctu.ucl.ac.uk/news/news-st... aidsconference.bsky.social

Infographic with LATA results. It reads:
LATA tested long-acting injectable cabotegravir and rilpivirine (CAB/RPV), given once every eight weeks, compared to daily TLD (tenofovir disoproxil, lamivudine and dolutegravir) tablets.
476 young people living with HIV in Sub-Saharan Africa
• 12-19 years old
• Already on treatment for ≥ 1 year
• HIV undetectable for ≥ 1 year
• No previous treatment failure
• Enrolled in Uganda, Kenya, Zimbabwe and South Africa
They were randomly allocated to one of these 2 groups:
Injections every 8 weeks
Daily tablets
Are long-acting injectables effective?
Proportion of young people with 2 consecutive viral loads ≥50 copies/mL by 96 weeks:
• Injections: 1%
• Daily tablets: 6%
Long-acting injectables were more effective than daily oral TLD tablets.
Are long-acting injectables safe?
• No differences in safety between groups
• Most people in the long-acting injectables group had mild injection-site reactions, usually pain, which quickly resolved.
What did young people think of long-acting injectables?
94% of people in the long-acting injectables group said it was a lot easier than taking daily medicines.
Conclusion: Long-acting injectable cabotegravir/rilpivirine are a highly effective and acceptable treatment option for young people living with HIV.
Logos: Innovative Clinical Trials Unit, Johnson & Johnson, EDCPT
LATA is funded by the European Developing Countries Clinical Trials Partnership (EDCTP) (grant number RIA2017MC-2005) and funding from Janssen Pharmaceutica NV.

012

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 28/07/2026

📢 Interested in health economics in clinical trials? Don't miss the upcoming webinar from the InCTU Capacity Strengthening Hub on "How to be a Good Trial Health Economist." 📅 30 July | 10:00 AM BST Link to register 👇

001

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 24/07/2026

Want to hear more? 🎙️Tune in to the latest Trial Talk podcast episode, where PediCAP team members Hilda Mujuru, Julia Bielicki and Michelle Clements discuss the trial, its innovative design and the newly published results. soundcloud.com/trial-talk-p...

soundcloud.com

PediCAP trial: Optimising treatment for children with severe community-acquired pneumonia

Children with community-acquired pneumonia are usually treated with an injectable antibiotic for five days. This often means staying in hospital for the full treatment period, even when they are well

010

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 24/07/2026

🆕 New publication alert! Results from the PediCAP trial show that children recovering from severe pneumonia can safely switch from injectable to oral antibiotics earlier, allowing them to come home from hospital sooner. @thelancet.com 🔗 Read more: www.innovative-ctu.ucl.ac.uk/news/news-st...

innovative-ctu.ucl.ac.uk

Children with severe pneumonia could leave hospital sooner with oral antibiotics | UCL Innovative Clinical Trials Unit

120

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 21/07/2026

Are you attending #AIDS2026? Don't miss the latest findings from our #HIV trials! Check out the list of talks & posters from the Innovative Clinical Trials Unit researchers and our partners: www.innovative-ctu.ucl.ac.uk/news/news-st... @iasociety.bsky.social

innovative Clinical Trials Unit at the AIDS 2026 Conference
Oral presentations:
Wednesday 29 July, 10:30AM (BRT): AIDS 2026-Co-chair's choice: "LATA 96-week results" (Mutsa Bwakura Dangarembizi)
Thursday 30 July, 10:30 AM (BRT): Ageing with HIV: Live long, live strong: "The impact of archived HIV-1 drug resistance on maintenance of virologic suppression through Week 48 in children aged 2 to <15 years receiving DTG/3TC: PENTA-21 intensive pharmacokinetic sub-study" (Ruolan Wang)

Innovative Clinical Trials Unit at the International Workshop on Pediatrics & HIV 2026
Posters
Predictors of viral non-suppression in children living with HIV initiating second-line antiretroviral therapy in the ODYSSEY and CHAPAS-4 trials (Pauline Amug)
HIV-1 resistance in children aged 2 to <15 years receiving DTG/3TC or DTG+2NRTI: results from the D3/PENTA-21 trial over 96 weeks (Johannes C Botha)
Prevalence of renal impairment in children and young adults living with HIV in Europe and Thailand (John O’Rourke)
T-Cell Subsets, T-Cell Receptor Repertoire and HIV-1 Virological Reservoir in Children Initiating First-Line Dolutegravir versus Standard-Of-Care ART: Results from the ODYSSEY Trial (Matt Byott (on behalf of Kathleen Gartner))

013

Reposted by UCL Innovative Clinical Trials Unit

Global Antibiotic R&D Partnership (GARDP) @gardp.bsky.social · 20/07/2026

A major milestone for GARDP's #NeoSep1 trial 🎉 The first baby has now been enrolled in Vietnam, continuing the expansion of this landmark neonatal sepsis trial from Africa into Asia.

112

Reposted by UCL Innovative Clinical Trials Unit

GESIS Training @gesistraining.bsky.social · 16/07/2026

Join our #GESISworkshop with @matteoq21.bsky.social & Tra My Pham (@innovative-ctu.bsky.social) to learn how to create, analyze, and report simulations in R/Stata. Discover when methods shine or fail, uncover their hidden biases, and compare alternatives. Registration ➡️ t1p.de/simulation_s...

GESIS Workshop
Using Simulation Studies to Evaluate Statistical Methods
19 - 20 & 26 - 27 November
Matteo Quartagno & Tra My Pham (both UCL)

013

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 16/07/2026

📢 Call for Digital Outcome Measures proposals for the AD-SMART trial The trial team is looking for validated, patient-friendly digital tools for AD-SMART, a trial accelerating the search for better and safer Alzheimer’s treatments. 🔗 More info: www.innovative-ctu.ucl.ac.uk/studies/all-...

innovative-ctu.ucl.ac.uk

AD-SMART call | UCL Innovative Clinical Trials Unit

001

Reposted by UCL Innovative Clinical Trials Unit

Global Antibiotic R&D Partnership (GARDP) @gardp.bsky.social · 06/07/2026

Every year, millions of newborns develop sepsis. For many, the antibiotics available are no longer effective. We're proud to announce the launch of the #NeoSep1 clinical trial at Aga Khan University Hospital in Pakistan, helping advance better treatment options for newborns with sepsis. #AMR

122

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 30/06/2026

🎧 New Trial Talk podcast! The ACORD collaboration is bringing together experts across disciplines to transform clinical trials for neurodegenerative diseases. Hear from James Carpenter and Ed Jabbari about the vision & impact of this collaboration 👉 soundcloud.com/trial-talk-p...

soundcloud.com

The ACORD collaboration: Innovative Clinical Trials for Neurodegenerative Diseases

ACORD is a pioneering collaboration that brings together experts from a wide range of disciplines to accelerate the development of treatments for neurodegenerative diseases. In this episode, we explor

010

Reposted by UCL Innovative Clinical Trials Unit

Global Antibiotic R&D Partnership (GARDP) @gardp.bsky.social · 24/06/2026

🚨 This is BIG! 👶JIPMER in India enrolled the first baby in Asia into the NeoSep1 trial. Since then, babies have been enrolled at the Rohtak site, with Mumbai next. 🧪 Led by GARDP and partners, NeoSep1 is one of the most ambitious clinical trials ever undertaken for neonatal sepsis.

143

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 18/06/2026

(5/5) These results mark a turning point in the treatment of staph blood infections, offering safer, effective options that could improve outcomes for patients worldwide. 🔗 Read the full story in our website: www.innovative-ctu.ucl.ac.uk/news/news-st...

innovative-ctu.ucl.ac.uk

SNAP trial shows safer antibiotic option for staph blood infection | UCL Innovative Clinical Trials Unit

000

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 18/06/2026

(4/5) SNAP also explored the same questions in children. This short video explains how the trial will continue to assess the best treatment for children and young people. 📺 youtu.be/53RW0lpibVY

youtu.be

The SNAP trial – children

YouTube video by UCL Innovative Clinical Trials Unit

100

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 18/06/2026

(3/5) Do you want a quick, expert overview of the SNAP trial? Watch this short video featuring Anna Goodman, UK lead of the SNAP trial, explaining the results and what they mean in clinical practice. 📺 youtu.be/sTK5wScWm5A

youtu.be

The SNAP trial – Results

YouTube video by UCL Innovative Clinical Trials Unit

100

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 18/06/2026

(2/5) SNAP researchers also found that penicillin can be used instead of flucloxacillin when the staph is treatable with this antibiotic in the lab. 📃 Read the publication in the Lancet: doi.org/S0140-6736(2...

Infographic: Title: "Which antibiotic should we be using to treat the most common types of Staphylococcus aureus bloodstream infections?
Treatment for S. aureus bloodstream infections
S. aureus: A leading cause of life-threatening blood infection
One common type of s. aureus bloodstream infection is: PSSA
Infections that could be treated with (Flu)cloxacillin or Penicillin.
Current UK standard therapy for PSSA infections: (Flu)cloxacillin
The SNAP clinical trial:
281 people with PSSA infections in their blood: ≥ 18 years old; from Australia, Canada, Israel, the Netherlands, New Zealand, Singapore, South Africa and the UK. Treated with one of PSSA antibiotics: (Flu)cloxacillin or Penicillin.
What did SNAP find?
Penicillin probably works as well as (flu)cloxacillin
Penicillin caused less harm to the kidney than (flu)cloxacillin
This means that penicillin is likely to be a better choice to treat S. aureus bloodstream infections

Funders:
Australia, Israel & South Africa - National Health and Medical Research Council
Canada - Canadian Institutes of Health Research & Accelerating Clinical Trials Consortium
The Netherlands - ZonMW Good Use of Medicines Program
New Zealand - Health Research Council of New Zealand
Singapore - Singapore National Medical Research Council clinical trial grant
UK - National Institute for Health and Care Research

100

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 18/06/2026

(1/5) The SNAP trial has found that a little used antibiotic, cefazolin, is as effective and safer as the standard therapy, flucloxacillin for treating life-threatening staph blood infections. 📃 Read the publication in the NEJM: doi.org/10.1056/NEJM....

100

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 18/06/2026

🚨New results from the SNAP trial! Researchers have identified the optimal antibiotics for staph blood infection, a serious global health issue. A thread 🧵👇

222

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 18/06/2026

(5/5) These results mark a turning point in the treatment of staph blood infections, offering safer, effective options that could improve outcomes for patients worldwide. 🔗 Read the full story on our website: www.innovative-ctu.ucl.ac.uk/news/news-st...

innovative-ctu.ucl.ac.uk

SNAP trial shows safer antibiotic option for staph blood infection | UCL Innovative Clinical Trials Unit

000

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 18/06/2026

(4/5) SNAP also explored the same questions in children. This short video explains how the trial will continue to assess the best treatment for children and young people. 📺 youtu.be/53RW0lpibVY

youtu.be

The SNAP trial – children

YouTube video by UCL Innovative Clinical Trials Unit

100

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 18/06/2026

youtu.be

The SNAP trial – Results

YouTube video by UCL Innovative Clinical Trials Unit

100

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 18/06/2026

100

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 18/06/2026

100

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 04/06/2026

🚨 New publication alert! Results from the SMAART-CHARISMA study show that artesunate (the standard treatment for severe malaria in children) remains effective, even in regions where drug resistance is rising in Africa. 🔗 Read more: www.imperial.ac.uk/news/article...

imperial.ac.uk

Standard malaria treatment still the best, even against resistant strains

Artesunate – the standard treatment for severe malaria in children – is still effective, even in regions of Africa where drug-resistant m...

010

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 02/06/2026

📈 News from the RAMPART trial! Results presented at #ASCO26 show that using the immunotherapy drug durvalumab alone does not lower the risk of kidney cancer coming back after surgery compared with active monitoring. 🔗 Read more: www.innovative-ctu.ucl.ac.uk/news/news-st...

innovative-ctu.ucl.ac.uk

Using two immunotherapy drugs together benefits people with kidney cancer | UCL Innovative Clinical Trials Unit

021

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 01/06/2026

We are excited to announce the launch of REFINE-MS! A new clinical trial for people living with relapsing-remitting MS, exploring whether treatment can be taken less often while still keeping disease activity under control. 🔗 Find out more: www.innovative-ctu.ucl.ac.uk/news/news-st...

innovative-ctu.ucl.ac.uk

A new trial for people living with relapsing-remitting multiple sclerosis launches in the UK | UCL Innovative Clinical Trials Unit

010

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 28/05/2026

Heading to #ASCO26? Don’t miss James Larkin presenting new RAMPART results on whether 1 or 2 immunotherapy drugs can reduce kidney cancer recurrence vs active monitoring. 📆 30 May, 8:36–8:48 AM CDT 📍Clinical Science Symposium 🔗More about RAMPART: www.innovative-ctu.ucl.ac.uk/studies/all-...

innovative-ctu.ucl.ac.uk

RAMPART | UCL Innovative Clinical Trials Unit

010

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 20/05/2026

And with this post, we wrap up our #ProudestOf campaign! Thank you to everyone who shared their proudest moments. It’s been fantastic to celebrate the people behind the work we do! 🙌 You can look back on all the inspiring moments by searching the hashtag #ProudestOf.

110

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 20/05/2026

Today is #InternationalClinicalTrialsDay 🌍 Patients and the public are at the heart of our research. Our #PPI group helps shape our trials, making them better, more relevant, and more inclusive. Today we’re asking our patient reps: What are you #ProudestOf in your work as part of the PPI group?

A quote from Ben, it reads "I am proud of the work our PPI group has done in providing training and support to new PPI representatives and researchers, helping to maximise the impact of PPI in every study. The rapid and innovative response to the need for PPI in COVID research, by developing the concept of a PPI panel, is another great achievement that is now being applied in other disease areas, such as TB."

A quote from Danielle, it reads "I am proudest of my involvement in promoting the use of the patient information sheet (PIS) developed by Dr Peter Knapp, ever since it was first presented at the INVOLVE conference. As a founder member of the Paediatric Oncology Reference Team (PORT), I made sure we adopted it for paediatric oncology trials. This made a significant difference for PORT, as we could make the PIS much more accessible. This is especially important with some children’s cancers, where Day 1 randomisation means families have very little time to get their head around things before making a decision for their child."

A quote from Ian, it reads "I am proud of our contribution to the success of clinical trials through our provision of advice for the Quality Management Advisory Group. We know it has made a positive difference to the studies in the eyes of the project PPI leads, who feel the review of documents has been excellent. The comments we provide prompt interesting discussions within the trial teams, leading to improvements in PPI processes."

A quote from Virginia, it reads "I’m proudest of the contribution we make to helping studies become easier for everyone to read and understand. Through PPI, we also encourage researchers to think about the real, practical realities of running a study and how best to involve participants. That’s where we really see the difference we make!"

272

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 18/05/2026

📈 New results from ARCHERY at #ESTRO26 The ARCHERY AI radiotherapy planning tool is effective in delivering timely and high-quality radiotherapy for the treatment of cervical cancer, contributing to the global effort to eliminate cervical cancer worldwide. 🔗 Read more:

buff.ly

AI tool for radiotherapy can support the global effort to eliminate cervical cancer | UCL Innovative Clinical Trials Unit

18 May 2026

000

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 15/05/2026

Heading to #ESTRO26? Don’t miss Ajay Aggarwal presenting the first results from ARCHERY: a global trial evaluating AI-based radiotherapy treatment. 📅 18 May 2026 ⏰ 14:10 (CEST) 📍 A1 Plenary ”Highlights: Latest trials.” 🔗More about ARCHERY: archery.mrcctu.ucl.ac.uk

archery.mrcctu.ucl.ac.uk

Home | ARCHERY

010